LCTX

Lineage Cell Therapeutics Inc

Add to Watchlist

Advanced Chart

0.951

-0.039(-3.940%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

1.020

Open

0.9986

VWAP

0.98

Vol

1.01M

Mkt Cap

217.12M

Low

0.950

Amount

989.47K

EV/EBITDA(TTM)

Total Shares

188.82M

176.88M

EV/OCF(TTM)

P/S(TTM)

21.85

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological and ophthalmic conditions. The Company’s programs are based on its cell-based technology platform and associated development and manufacturing capabilities. From this platform, it designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions. Its neuroscience focused pipeline includes OpRegen, a retinal pigment epithelial cell therapy in phase II a development, for the treatment of geographic atrophy secondary to age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy in phase I/II a development for the treatment of spinal cord injuries; ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and RND1.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

1.84M

-35.97%

1.89M

-50.02%

1.47M

+4.59%

Estimates Revision

The market is revising Downward the revenue expectations for Lineage Cell Therapeutics, Inc. (LCTX) for FY2025, with the revenue forecasts being adjusted by -42.41% over the past three months. During the same period, the stock price has changed by 114.14%.

Revenue Estimates for FY2025

Revise Downward

-42.41%

In Past 3 Month

Stock Price

Go Up

+114.14%

In Past 3 Month

4 Analyst Rating

334.37% Upside

Wall Street analysts forecast LCTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LCTX is 4.13 USD with a low forecast of 1.50 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

334.37% Upside

Current: 0.951

Low

1.50

Averages

4.13

High

9.00

334.37% Upside

Current: 0.951

Low

1.50

Averages

4.13

High

9.00

B. Riley Securities

Mayank Mamtani

Strong Buy

Maintains

$4 → $3

2025-03-14

Reason

B. Riley Securities

Mayank Mamtani

Price Target

$4 → $3

2025-03-14

Maintains

Strong Buy

Reason

B. Riley analyst Mayank Mamtani lowered the firm's price target on Lineage Cell Therapeutics (LCTX) to $3 from $4 and keeps a Buy rating on the shares. Lineage Cell Therapeutics' Q4 recap focused on Roche (RHHBY)-partnered OpRegen program, steadily advancing earlier-stage wholly-owned programs, and Lineage's dominant position in large-scale allogeneic manufacturing to produce millions of retinal pigment epithelium cells, the analyst tells investors in a research note. The OpRegen dry AMD opportunity could come through the ongoing Phase II GAlette study interim data release, and Roche opting to progress to a randomized controlled study to confirm high efficacy benefits noted with optimized delivery system in sizeable patient population, the firm says.

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

2025-03-11

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

2025-03-11

Reiterates

Strong Buy

Reason

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

2025-03-11

Reason

D. Boral Capital

Jason Kolbert

Price Target

2025-03-11

Maintains

Strong Buy

Reason

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$3 → $2

2025-02-11

Reason

D. Boral Capital

Jason Kolbert

Price Target

$3 → $2

2025-02-11

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

2025-01-31

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

2025-01-31

Reiterates

Strong Buy

Reason

Maxim Group

Michael Okunewitch

Strong Buy

Maintains

$5 → $3

2025-01-10

Reason

Maxim Group

Michael Okunewitch

Price Target

$5 → $3

2025-01-10

Maintains

Strong Buy

Reason

Maxim lowered the firm's price target on Lineage Cell Therapeutics (LCTX) to $3 from $5 and keeps a Buy rating on the shares. Sana Biotechnology (SANA), another player in the cell transplant therapeutic space, has announced positive results for its hypoimmune pancreatic islet cell therapy, which represents a positive signal for the space and further validation of the potential for cell transplant therapies like UP421, OpRegen, and OPC1, the analyst tells investors in a research note. The firm adds however that it is reducing its price target to reflect the dilution from the company's November financing.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Lineage Cell Therapeutics Inc (LCTX.A) is -11.63, compared to its 5-year average forward P/E of -9.01. For a more detailed relative valuation and DCF analysis to assess Lineage Cell Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-9.01

Current PE

-11.63

Overvalued PE

-5.53

Undervalued PE

-12.50

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-13.34

Current EV/EBITDA

-6.52

Overvalued EV/EBITDA

12.79

Undervalued EV/EBITDA

-39.46

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

44.08

Current PS

15.83

Overvalued PS

93.94

Undervalued PS

-5.77